RT @DrKanikaMonga: - Risk of bDMARD withdrawal higher for TNFi monotherapy compared w/ cs/bDMARD combination - If monotherapy necessary, et…

Social Author Image
https://pbs.twimg.com/profile_images/1083541200341106689/TcYPzt_E.jpg
Tweet Author
DrKanikaMonga
Social Author Name
Kanika Monga, MD
Tweet Content
- Risk of bDMARD withdrawal higher for TNFi monotherapy compared w/ cs/bDMARD combination - If monotherapy necessary, etanercept should be preferred over infliximab and adalimumab Silvagni E et al. BMJ Open 2018 #ACR19 @RheumNow
Show on Archive Page
On
Display in Search Results
On

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×